| Eiger BioPharmaceuticals is a biopharmaceutical company. Co. has five product candidate pipeline programs: Lonafarnib (LNF) in Hepatitis Delta Virus (HDV), which is an orally bioavailable, farnesylation inhibitor for HDV infection; Peginterferon Lambda in HDV, which is a type III interferon that stimulates immune responses that are key for the development of host protection during viral infections; LNF in Progeria and Progeroid Laminopathies (PL), in which it is developing LNF for treatment of Progeria and PL; Avexitide in Post-Bariatric Hypoglycemia (PBH), in which it is developing as a treatment for PBH; and Avexitide in Congenital Hyperinsulinism (CHI), which is a treatment for CHI. We show 22 historical shares outstanding datapoints in our coverage of EIGR's shares outstanding history.|
Understanding the changing numbers of EIGR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like EIGR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching EIGR by allowing them to research EIGR shares outstanding history
as well as any other stock in our coverage universe.